Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Phase 2
1(16.7%)
6Total
Phase 1(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT04776317Phase 1Completed

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

Role: collaborator

NCT05456165Phase 2Withdrawn

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Role: lead

NCT05148962Phase 1Completed

Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers

Role: lead

NCT05435027Phase 1Completed

Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)

Role: lead

NCT03953235Phase 1Completed

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Role: lead

NCT03639714Phase 1Completed

A Study of a Personalized Neoantigen Cancer Vaccine

Role: lead

NCT05158621Completed

A Screening Study Targeting Tumor-specific Antigens

Role: lead

NCT03794128Completed

A Study of Personalized Neoantigen Cancer Vaccines

Role: lead

All 8 trials loaded